XiaoXia Wei1, JiaQin Cai1, Hong Sun1, Na Li2, Chenxia Xu2, Guifeng Zhang3, Yuxia Sui1, Jie Zhuang1, Bin Zheng2,4. 1. Department of Pharmacy, Fujian Provincial Hospital, Provincial Clinical Medicine College of Fujian Medical University, Fuzhou 350001, Fujian Province, PR China. 2. Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, PR China. 3. Department of Oncology, Fujian Provincial Hospital, Provincial Clinical Medicine College of Fujian Medical University, Fuzhou 350001, Fujian Province, PR China. 4. The School of Pharmacy, Fujian Medical University, Fuzhou 350001, Fujian Province, PR China.
Abstract
AIM: To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China. MATERIALS & METHODS: A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. One-way sensitivity analyses were performed. RESULTS: The strategy of genotyping with dose reduction dominated all remaining strategies. Compared with the strategies of no genotyping and genotyping with unchanged dose, it resulted in only marginal quality-adjusted life year increases (0.0011 and 0.0012) but a cost reduction of $651.12 and $805.22 per patient, respectively. One-way sensitivity analyses revealed that the model was relatively robust. CONCLUSION: UGT1A1*6/*28 genotyping was cost saving for Chinese colorectal cancer patients.
AIM: To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China. MATERIALS & METHODS: A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. One-way sensitivity analyses were performed. RESULTS: The strategy of genotyping with dose reduction dominated all remaining strategies. Compared with the strategies of no genotyping and genotyping with unchanged dose, it resulted in only marginal quality-adjusted life year increases (0.0011 and 0.0012) but a cost reduction of $651.12 and $805.22 per patient, respectively. One-way sensitivity analyses revealed that the model was relatively robust. CONCLUSION:UGT1A1*6/*28 genotyping was cost saving for Chinese colorectal cancerpatients.
Authors: Megan L Hutchcraft; Nan Lin; Shulin Zhang; Catherine Sears; Kyle Zacholski; Elizabeth A Belcher; Eric B Durbin; John L Villano; Michael J Cavnar; Susanne M Arnold; Frederick R Ueland; Jill M Kolesar Journal: Cancers (Basel) Date: 2021-09-08 Impact factor: 6.639
Authors: Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks Journal: Cancers (Basel) Date: 2021-03-29 Impact factor: 6.639